Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2026)

Amneal Pharmaceuticals' Operating Expenses history runs 10 years deep, the most recent figure standing at $177.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 12.36% year-over-year to $177.9 million; the TTM figure through Mar 2026 stood at $736.2 million (up 9.15% YoY), while the FY2025 annual figure was $717.2 million, up 7.13% from the prior year.
• Operating Expenses was $177.9 million for Q1 2026 at Amneal Pharmaceuticals, down from $183.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $201.3 million in Q3 2025 to a low of $141.3 million in Q1 2023.
• Historically, Operating Expenses has averaged $162.1 million across 5 years, with a median of $155.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses declined 8.28% in 2022, then gained 18.2% in 2024.
• A 5-year view of Operating Expenses shows it stood at $143.5 million in 2022, then advanced by 8.19% to $155.2 million in 2023, then increased by 18.2% to $183.4 million in 2024, then rose by 0.16% to $183.7 million in 2025, then fell by 3.19% to $177.9 million in 2026.
• The last three Operating Expenses figures came in at $177.9 million (Q1 2026), $183.7 million (Q4 2025), and $201.3 million (Q3 2025), per Business Quant data.